At a glance
ClinicalIndex Comparison Record- ✓Histologically-confirmed recurrent ovarian, fallopian tube, primary peritoneal cancer, endometrial, vaginal, or cervical cancer in the abdomen and pelvis
- ✓Stage IV disease eligible if distant disease undetectable/stable (≥3 months) and no immediate chemotherapy needed
- ✓At least one lesion ≥10 mm (≥15 mm for lymph nodes) not previously irradiated, measurable by CT or MRI
- ✓Life expectancy ≥16 weeks
- ✕Ascites, peritoneal carcinomatosis, or hepatic metastases
- ✕Prior radiotherapy in region of planned radiotherapy
- ✕Chemotherapy, radiotherapy, endocrine therapy, immunotherapy, or investigational agents within 3 weeks prior to therapy start
- ✕Previous enrollment in this study
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers
In Brief
A Phase 1 clinical trial evaluating Quality-of-Life Assessment, Radiation Therapy, and 1 other intervention for Malignant Female Reproductive System Neoplasm and 24 related conditions. Currently recruiting, targeting 24 participants across 2 sites.
Detailed Summary
This phase I trial studies the side effects and best dose of talazoparib in combination with radiation therapy and to see how well they work in treating patients with gynecologic cancers that have come back after previous treatment (recurrent). Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving talazoparib in combination with radiation therapy may work better in treating patients with gynecologic cancers.
Study Details
Timeline
Interventions
Ancillary studies
Undergo radiation therapy
Given PO